{"entity":{"id":"john-byrd","kind":"person","name":"John C. Byrd","aka":[],"tldr":"Led the ibrutinib trials that turned CLL from a chemotherapy disease into one treated with pills.","summary":"John Byrd (University of Cincinnati; formerly Ohio State) led the pivotal phase 1b/2 and RESONATE trials of ibrutinib in chronic lymphocytic leukaemia, the results that made BTK inhibition the standard of care and displaced chemoimmunotherapy, and the ELEVATE-RR head-to-head trial showing acalabrutinib is better tolerated. His laboratory helped develop acalabrutinib and continues work on resistance and AML therapeutics.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Byrd%20JC%5BAuthor%5D%20chronic%20lymphocytic%20leukemia%20ibrutinib"}],"tags":["cll","btk","targeted-therapy"],"related":[],"cancers":["cll"],"sections":[],"technologies":["kinase-inhibitors"],"targets":[],"drugs":[],"companies":[],"institutions":["cincinnati-cancer-center"],"pathways":[],"terms":[],"trials":["resonate","elevate-tn"],"people":[],"bottlenecks":[],"keyPapers":["paper-elevate-tn-acalabrutinib-lancet-2020"],"journals":[],"dependsOn":[],"notes":[],"role":"Chair, Department of Internal Medicine, University of Cincinnati College of Medicine","institutionId":"cincinnati-cancer-center","specialisms":["Chronic lymphocytic leukaemia","BTK inhibitors","Drug development","Leukaemia biology"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Byrd%20JC%5BAuthor%5D%20chronic%20lymphocytic%20leukemia%20ibrutinib"}],"papers":[{"title":"Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia","journal":"NEJM","year":2013,"doi":"10.1056/NEJMoa1215637"},{"title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia (RESONATE)","journal":"NEJM","year":2014,"doi":"10.1056/NEJMoa1400376"},{"title":"Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial (ELEVATE-RR)","journal":"JCO","year":2021,"doi":"10.1200/JCO.21.01210"},{"title":"ELEVATE-TN: acalabrutinib, alone or with obinutuzumab, against chemo-immunotherapy in untreated CLL","journal":"The Lancet","year":2020,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=ELEVATE-TN%20acalabrutinib%20obinutuzumab%20chlorambucil%20Sharman%20Lancet%202020"}]},"route":"/people/john-byrd/","neighbours":{"cancer":[{"id":"cll","kind":"cancer","name":"Chronic lymphocytic leukaemia","route":"/cancers/cll/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"institution":[{"id":"cincinnati-cancer-center","kind":"institution","name":"University of Cincinnati Cancer Center","route":"/institutions/cincinnati-cancer-center/"}],"trial":[{"id":"beat-aml-master-trial","kind":"trial","name":"Beat AML Master Trial","route":"/trials/beat-aml-master-trial/"},{"id":"elevate-tn","kind":"trial","name":"ELEVATE-TN","route":"/trials/elevate-tn/"},{"id":"resonate","kind":"trial","name":"RESONATE","route":"/trials/resonate/"}],"paper":[{"id":"paper-elevate-tn-acalabrutinib-lancet-2020","kind":"paper","name":"ELEVATE-TN: acalabrutinib, alone or with obinutuzumab, against chemo-immunotherapy in untreated CLL","route":"/key-papers/paper-elevate-tn-acalabrutinib-lancet-2020/"}]}}